Bausch + Lomb (BLCO) reported $1.28 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 5.1%. EPS of $0.07 for the same period compares to $0.13 a year ago.
The reported revenue represents a surprise of +2.37% over the Zacks Consensus Estimate of $1.25 billion. With the consensus EPS estimate being $0.06, the EPS surprise was +16.67%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Bausch + Lomb performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Vision Care: $753 million compared to the $742.89 million average estimate based on three analysts. The reported number represents a change of +8% year over year.
- Revenues- Surgical: $216 million versus the three-analyst average estimate of $180.14 million. The reported number represents a year-over-year change of +3.4%.
- Revenues- Pharmaceuticals: $309 million versus $329.52 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.3% change.
- Revenues- Product sales: $1.27 billion compared to the $1.25 billion average estimate based on three analysts. The reported number represents a change of +4.9% year over year.
- Revenues- Other revenues: $6 million versus $4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +100% change.
View all Key Company Metrics for Bausch + Lomb here>>>
Shares of Bausch + Lomb have returned +8.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bausch + Lomb Corporation (BLCO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
